KEY DETAILS
As GLP-1 users eat less, food makers are adding protein and fiber to familiar brands, and J.P. Morgan says food and drink sales could fall by as much as $55 billion by 2030.
As we reported on September 18, Martha Stewart's promotion of a GLP-1 drug she says she does not take has raised ethics questions about celebrity endorsements.
Also covered on September 18: Chrissy Metz has spoken publicly about her GLP-1 weight loss while facing criticism for taking the medication at all.
As GLP-1 users eat less, food makers are adding protein and fiber to familiar brands, and J.P. Morgan says food and drink sales could fall by as much as $55 billion by 2030. If you're on one of these medications, that shift is already showing up in what you find at the store. We also follow up on two stories from September 18: a pointed question about who gets to sell these drugs, and a public defense from someone living the experience firsthand.
That reshaping is already visible in what food makers are putting on shelves. Brands are adding protein or fiber to familiar products, from protein Doritos and high-protein Kraft Mac & Cheese to Campbell's soups with 20 grams of protein a can. Restaurants are adjusting too: Olive Garden added a Lighter Portions menu. Clothing retailers are also seeing customers buy smaller sizes, another sign these drugs are changing everyday purchasing habits. For food companies, adjusting to this shift is proving difficult. If you use a GLP-1 medication, you may already have noticed you need less at the store than you used to, and it looks like the industry is finally catching up to that reality.
That same commercial interest in GLP-1 drugs is also drawing sharper questions about who profits from promoting them. As we reported on September 18, Martha Stewart has come under criticism for advertising a GLP-1 medication despite saying publicly that she does not take it herself. Critics have asked directly, as one commenter put it, "How the hell can you be a spokesperson for a GLP-1 when you don't even take it??" The criticism raises a broader ethical question about celebrity endorsements in this market, and whether audiences deserve to know when a spokesperson's own experience does not match the product they are selling.
Chrissy Metz, also covered here on September 18, has taken the opposite approach, speaking openly about her own GLP-1 weight loss experience rather than staying silent about it. She has faced criticism for her choice, but has defended her decision publicly, treating it as her own experience to explain on her own terms. Where Stewart is questioned for promoting something she reportedly doesn't use, Metz is being questioned for using something at all, which shows how differently the public reacts depending on whether a celebrity is closer to or further from these drugs. Either way, both stories point to how much scrutiny public figures now face around GLP-1 use, whether they take the medication or simply sell it.
None of this changes how these drugs work for the person taking them, but it does show how far their effects reach into everyday life, from grocery aisles to celebrity endorsements. If you're shopping while on a GLP-1 medication, it may be worth reading labels on the new high-protein and high-fiber versions of familiar foods, since that shift is underway. And if you follow public figures who talk about these drugs, it's reasonable to ask what their actual experience is, whether they're selling a product or simply sharing their own story. Paying attention to that distinction can help you separate marketing from lived experience.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.